A Broadly Neutralizing Human Anti-HIV Monoclonal Antibody (10E8) Capable of Neutralizing Most HIV-1 Strains

This Human Anti-HIV Monoclonal Antibody (10E8) has great potential to provide passive protection from infection, as a therapeutic vaccine, or as a tool for the development of vaccine immunogens. 10E8 is one of the most potent HIV-neutralizing antibodies isolated thus far and it can potently neutralize up to 98% of genetically diverse HIV-1 strains. 10E8 is specific to the membrane-proximal external region (MPER) of the HIV envelope protein, GP41. It is anticipated that 10E8 could be used in combination with another human anti-HIV-1 monoclonal antibody to provide an antibody response that neutralizes nearly all strains of HIV-1. Additionally, 10E8 is a useful tool for the design of vaccine immunogens that can elicit an adaptive immune response to produces 10E8 like antibodies. This technology also includes monoclonal antibodies from the same germ line as 10E8.

Potential Commercial Applications: Competitive Advantages:
  • Passive protection to prevent HIV infection
  • Passive protection to prevent mother-to-infant HIV transmission
  • Topical microbicide to prevent HIV infection
  • Gene-based vectors for anti-gp41 antibody expression
  • Therapeutic for the elimination of HIV infected cells that are actively producing virus
  • One of the most potent Human broadly-neutralizing anti HIV antibodies isolated to date
  • Broad reactivity and high affinity to most HIV-1 strains
  • Activity is highly complementary to existing broadly neutralizing antibodies, such as CD4 binding site antibodies
  • Capable of neutralizing all HIV-1 strains, if used in combination with another anti-HIV monoclonal antibody

Related Inventoion(s):

Mark Connors (NIAID)

Intellectual Property:
US Application No. 61/556,660

Collaboration Opportunity:

The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize vaccine immunogens capable of eliciting a 10E8-like adaptive immune response. For collaboration opportunities, please contact Bill Ronnenberg at 301-451-3522 or wronnenberg@niaid.nih.gov.

Licensing Contact:
Cristina Thalhammer-Reyero , Ph.D., M.B.A.
NIH Office of Technology Transfer
Email: thalhamc@mail.nih.gov
Phone: 301-435-4507

OTT Reference No: E-253-2011/0

Updated: May-01-2012